Contamination rates and antimicrobial resistance in bacteria isolated from "grass-fed" labeled beef products.
ABSTRACT Grass-fed and organic beef products make up a growing share of the beef market in the United States. While processing, animal handling, and farm management play large roles in determining the safety of final beef products, grass-fed beef products are often marketed as safer alternatives to grain-finished beef products based on the potential effects of all-forage diets on host microbiota. We conducted a series of experiments examining bacterial contamination rates in 50 beef products labeled as "grass-fed" versus 50 conventionally raised retail beef products. Coliform concentrations did not differ between conventional and grass-fed beef (conventional: 2.6 log(10) CFU/mL rinsate; grass-fed: 2.7 log(10) CFU/mL rinsate). The percentages of Escherichia coli positive samples did not differ between the two groups (44% vs. 44%). Enterococcus spp. were frequently isolated from both grass-fed beef products (44%) and conventional beef products (62%; p = 0.07). No Salmonella or E. coli O157:H7 isolates were recovered from any of the meat samples. Enterococcus spp. isolates from conventional beef were more frequently resistant to daptomycin and linezolid (p < 0.05). Resistance to some antimicrobials (e.g., chloramphenicol, erythromycin, flavomycin, penicillin, and tetracyline) was high in Enterococcus spp. isolated from both conventional and grass-fed beef. There were no differences in the percentages of antimicrobial resistant E. coli isolates between the two groups. Taken together, these data indicate that there are no clear food safety advantages to grass-fed beef products over conventional beef products.
- Journal of Medical Microbiology 04/2013; · 2.27 Impact Factor
- [Show abstract] [Hide abstract]
ABSTRACT: Resistance to daptomycin in enterococcal clinical isolates remains rare, but is being increasingly reported in the U.S. and worldwide. There is limited data on the genetic relatedness, microbiological and clinical characteristics of daptomycin-nonsusceptible enterococcal clinical isolates. In this study, we assessed the population genetics of daptomycin-nonsusceptible Enterococcus faecium (DNSE) clinical isolates by multilocus sequence typing (MLST) and whole genome sequencing analysis. Forty-two non-duplicate DNSE isolates and 43 randomly selected daptomycin-susceptible E. faecium isolates were included in the analysis. All E. faecium isolates were recovered from patients at a tertiary care medical center in suburban New York City from May 2009 through December 2013. The daptomycin MICs of the DNSE isolates varied from 6 to >256 μg/ml. Three major clones of E. faecium (ST18, ST412 and ST736) were identified among these clinical isolates by MLST and whole genome sequence-based analysis. A newly recognized clone ST736 was seen in 32 of 42 (76.2%) DNSE isolates, and in only 14 of 43 (32.6%) of daptomycin-susceptible E. faecium isolates (p < 0.0001). This study provides evidence of the association between E. faecium clone ST736 and daptomycin nonsusceptibility. The identification and potential spread of this novel E. faecium clone and its association with daptomycin nonsusceptibility constitutes a challenge for patient management and infection control at our medical center.Antimicrobial Agents and Chemotherapy 06/2014; · 4.45 Impact Factor
- [Show abstract] [Hide abstract]
ABSTRACT: Daptomycin non-susceptible Enterococcus (DNSE) is an emerging clinical problem. Little is known about how de novo DNSE infections develop or the risk factors associated with them. Determining risk factors associated with de novo DNSE infections will aid in understanding the mechanisms of daptomycin non-susceptibility. Humans in contact with animals worldwide are at risk of carriage of multidrug-resistant bacteria. Herein, I review the scientific evidence that supports the hypothesis that transport of daptomycin non-susceptibility genes between animals and humans may be a possible mechanism for development of de novo daptomycin non-susceptibility in enterococci.Zoonoses and Public Health 11/2013; · 2.09 Impact Factor